Hyperactive signaling pathways of some aggressive blood cancer cells can be tamped down by a previously unrecognized protein complex, ensuring the cancer's survival. If one component of the complex is ...

Scientists at the University of Lausanne (UNIL) and University center Unisanté classified 35 commonly used drugs in Switzerland based on their impact on the aquatic biodiversity. The aim of this ...

Researchers looked specifically at head-to-head randomized clinical trials of next-in-class cancer drugs against existing agents in the same class. Less than one-quarter of next-in-class cancer drugs ...

When Katelynn O’Connell takes her lunch break at work, she follows a routine that sets her apart from other employees. Each day at noon, she unfolds a cot in her small office, turns on a white noise ...

Scientists remain puzzled as to why some individuals taking popular weight loss and diabetes medications such as Ozempic and Wegovy develop complications with their eyesight, highlighting that we ...

Health Affairs' Senior Deputy Editor Rob Lott interviews Jihye Han of Brigham and Women's Hospital and Harvard University on her recent paper that takes a closer look at the regulatory treatments for ...

The popular class of antidiabetic and weight loss drugs known as GLP-1RAs, which includes Ozempic and Wegovy, has been found to significantly reduce the risk of 10 out of 13 obesity-associated cancers ...

The number of Massachusetts residents prescribed a relatively new class of drugs used for diabetes and weight management has increased sevenfold over five years, at a staggering cost, according to a ...

Absci Corporation (ABSI) is working on developing the use of its biological drug ABS-101 for the treatment of patients with inflammatory bowel disease [IBD]. This drug is already de-risked in the fact ...

More than 8 million people in the U.S. take blood thinners, also called anticoagulants. Many are prescribed the drugs after ...

In 22.2% of trials, there was a survival benefit with the next-in-class agent. Less than one-quarter of next-in-class cancer drugs demonstrated a survival benefit over existing in-class agents in head ...